Hamps Bio Ltd.

As of March 31, 2026, Hamps Bio Ltd. carries a market capitalization of 144.18M, placing it among publicly traded companies globally. Its enterprise value stands at 211.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Hamps Bio Ltd. has 8.71M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Hamps Bio Ltd. maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 21, 2026, Hamps Bio Ltd.'s stock has gained approximately 14.47% over the past 52 weeks. The 50-day moving average sits at 24.80, while the 200-day moving average is 23.12.

As of March 31, 2026, Hamps Bio Ltd. holds 1.70M in cash and equivalents against 68.83M in total debt, resulting in a net debt position of 67.13M. Total book value stands at 81.01M, with working capital of 16.80M providing operational flexibility.

Hamps Bio Ltd.'s most recent stock split took place on September 11, 2025 with a 1:2 split ratio.